1. Home
  2. TRMD vs ABCL Comparison

TRMD vs ABCL Comparison

Compare TRMD & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TORM plc

TRMD

TORM plc

N/A

Current Price

$34.29

Market Cap

3.5B

ML Signal

N/A

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

N/A

Current Price

$12.18

Market Cap

4.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TRMD
ABCL
Founded
1889
2012
Country
United Kingdom
Canada
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
4.1B
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
TRMD
ABCL
Price
$34.29
$12.18
Analyst Decision
Buy
Strong Buy
Analyst Count
2
13
Target Price
★ $44.50
$18.00
AVG Volume (30 Days)
1.5M
★ 3.2M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
★ 15.02%
N/A
EPS Growth
N/A
★ 10.91
EPS
★ N/A
N/A
Revenue
N/A
★ $75,128,000.00
Revenue This Year
$54.24
N/A
Revenue Next Year
N/A
$16.61
P/E Ratio
$9.61
★ N/A
Revenue Growth
N/A
★ 160.56
52 Week Low
$19.30
$2.75
52 Week High
$43.31
$14.98

Technical Indicators

Market Signals
Indicator
TRMD
ABCL
Relative Strength Index (RSI) 36.48 49.60
Support Level $31.76 $11.78
Resistance Level $34.47 $13.21
Average True Range (ATR) 1.62 0.99
MACD -0.94 -0.03
Stochastic Oscillator 11.62 44.84

Price Performance

Historical Comparison
TRMD
ABCL

About TRMD TORM plc

TORM PLC operates as a shipping company mainly owning and operating a fleet of product tankers. It is engaged in the transportation of refined oil products and clean petroleum products, including gasoline, jet fuel, naphtha, and diesel oil. The Company operates through two segments: the Tanker segment and the Marine Engineering segment, deriving the majority of its revenue from the Tanker segment.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: